Get a browser notification when a story in your categories carries a High or Critical risk / opportunity signal. Max 5 alerts a day.
The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026 — a new daily-pill add-on for ...